TipRanks on MSN
Bristol-Myers Squibb’s New Phase 3 Study: A Potential Game-Changer for Bipolar-I Disorder Treatment
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...
Bipolar disorder treatment often includes some combination of medications like mood stabilizers and antidepressants alongside therapy.
News Medical on MSN
BD² expands global effort to examine the key mechanisms of bipolar disorder
Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research ...
Each month, The Clinical Advisor makes one new clinical feature available ahead of print. Don’t forget to take the poll. The results will be published in the next month’s issue. Bipolar disorder is a ...
Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Bristol-Myers Squibb Company (BMY) ...
An antipsychotic approved by the FDA in 2009 to treat schizophrenia has now been green-lighted for use in bipolar 1 disorder. Iloperidone (Fanapt) is now FDA-approved for adults with bipolar 1 ...
BD² recently announced a fourth round of funding opportunities, inviting teams to apply for up to $4.5 million per grant to undertake groundbreaking research into the genetic, molecular, cellular, ...
Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can impact daily functioning and behavior. Although bipolar disorder is a chronic ...
Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...
News-Medical.Net on MSN
Mount Sinai receives $4.5 million grant to investigate neural mechanisms underlying bipolar disorder
The Icahn School of Medicine at Mount Sinai is pleased to announce it has received a three-year, $4.5 million grant from BD2: ...
As a premier non-profit behavioral health system, our residential program for boys and girls, ages 6-17, treats a wide range of mental health disorders. We also offer a dual diagnosis program for ...
The first IOP we offer is an in-person group for those struggling with mental health diagnoses (Anxiety, Depression, Bipolar, PTSD, etc.). This group meets Mondays, Wednesdays, and Fridays from 2:00-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback